Can psychedelic-inspired medicines deliver therapeutic benefits without the trip? Meditech Today explores this emerging approach, featuring Enveric’s lead non-hallucinogenic neuroplastogen candidate, EB-003. meditechtoday.com/next-psych… #EB003 $ENVB

Latest EB-003 results featured in Benzinga. The coverage highlights positive results from more than 70 IND-enabling ADMET assays, providing further support for EB-003's preclinical safety profile, and more. Read the full article: benzinga.com/news/health-car… #EnvericBiosciences #EB003 #Neuroplastogens #DrugDevelopment #Neuroscience #Biotech $ENVB

Enveric announced positive results from completed IND-enabling ADMET studies for its lead non-hallucinogenic neuroplastogen candidate, EB-003. Read the full announcement: enveric.com/news/ #EnvericBiosciences #EB003 #Neuroplastogens #DrugDevelopment #Biotech $ENVB

Nearly 1 in 7 people worldwide live with a mental disorder. At Enveric, we’re working to help address that need by developing next-generation neuroplastogens, including EB-003, designed to promote neuroplasticity without inducing hallucinations. Find out more at Enveric.com

Research highlighted by the NIH found evidence that depression may disrupt the development of new neurons in the hippocampus. EB-003 is being developed as a next-generation neuroplastogen designed to promote neuroplasticity without inducing hallucinations. Read the NIH research overview: nih.gov/news-events/nih-rese… #Depression #Neuroplasticity #Neuroplastogens #Neuroscience #MentalHealth #DrugDevelopment #Biotech $ENVB

Nearly 1 in 7 people worldwide live with a mental disorder. At Enveric, we’re working to help address that need by developing next-generation neuroplastogens, including EB-003, designed to promote neuroplasticity without inducing hallucinations. #MentalHealth #Depression #Anxiety #Neuroplasticity #Neuroplastogens #Neuroscience #DrugDevelopment #ENVB

New research highlighted by UCSF found that psilocybin increased connectivity between different regions of the brain in people with depression, adding to growing evidence that changes in brain plasticity and connectivity may be important to how new psychiatric therapies work. At Enveric, we are approaching that biology through drug design. Our lead candidate, EB-003, is being developed as a next-generation neuroplastogen designed to promote neuroplasticity without inducing hallucinations. EB-003 is designed to engage 5-HT2A and 5-HT1B receptors as Enveric works to translate advances in neuroscience into a potential medicine for neuropsychiatric disorders including depression and anxiety. EB-003 is currently progressing through IND-enabling development toward planned first-in-human studies. The more we understand about how the brain adapts and reorganizes, the more precisely we can design medicines intended to influence those processes. Find out more about EB-003 at Enveric.com #Neuroplasticity #Neuroplastogens #Depression #Neuroscience #MentalHealth #DrugDevelopment #Biotech #ENVB

EB-003 is designed to engage 5-HT2A and 5-HT1B receptors, with the goal of harnessing pathways associated with neuroplasticity. The program is currently advancing through IND-enabling development as Enveric works toward bringing EB-003 into first-in-human clinical studies.

At Enveric, our work is focused on developing neuroplastogens designed to promote adaptive changes in the brain, with EB-003 being advanced as a potential treatment for neuropsychiatric disorders including depression and anxiety. nih.gov/news-events/nih-rese…

The USPTO has issued a new NoA covering novel compounds within our EVM401 Series, a proprietary portfolio of non-hallucinogenic, mescaline-derived compounds designed to promote neuroplasticity. businesswire.com/news/home/2…

On September 14, the FDA will hold a public hearing focused on the future therapeutic use of psychedelic drugs in supervised and supportive settings. Enveric is taking a different approach with EB-003, a neuroplastogen designed to promote neuroplasticity without inducing hallucinations, with the goal of developing a treatment that could fit more easily into existing healthcare settings. Read more about the FDA hearing fda.gov/news-events/fda-meet…

Enveric will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16 in New York City. The virtual presentation will be available beginning September 11 at 7:00 a.m. ET. Learn more: enveric.com/investors/news/

Can researchers harness the neuroplasticity associated with psychedelic-inspired compounds while developing medicines that fit more naturally within existing healthcare systems? That question is central to the development of EB-003, our lead non-hallucinogenic neuroplastogen candidate. Find out more about our pipeline programs at Enveric.com #Neuroplastogens #Neuroplasticity #Neuroscience #MentalHealthInnovation #DrugDevelopment #Biotech #ENVB

Recent work has generated additional preclinical evidence supporting EB-003's intended non-hallucinogenic profile, while IND-enabling activities continue in preparation for a planned IND submission and Phase 1 clinical trial. Learn more about EB-003 and our development pipeline.

In a new Clinical Leader interview, Dr. Tucker discusses what the FDA’s latest guidance could mean for drug developers and why the distinction between psychedelic and non-hallucinogenic approaches matters. clinicalleader.com/doc/what-…

A new Microdose feature takes a closer look at Enveric's latest preclinical data for EB-003 and how it builds on findings reported earlier this year. Read the full article: microdose.buzz/news/enveric-…

New preclinical data from Enveric demonstrate that EB-003 did not produce behavioral effects associated with hallucinations - maintaining activity consistent with its intended MoA. benzinga.com/news/health-car… #Neuroplastogens #Neuroplasticity #MentalHealthInnovation #Neuroscience #DrugDevelopment #Biotech $ENVB

Today, Enveric announced new preclinical data demonstrating that EB-003 exhibited signaling characteristics consistent with a non-hallucinogenic profile in a highly sensitive GloSensor™ cAMP assay. Read the full announcement: enveric.com/investors/news/ $ENVB

At Enveric, our lead candidate, EB-003, was purpose-designed to engage neuroplasticity-related signaling while avoiding a hallucinogenic experience, reflecting this broader evolution in the field. Read the full article: meditechtoday.com/big-pharma…

The FDA’s finalized guidance marks an important step in the maturation of psychedelic and psychedelic-inspired drug development. The guidance does not make development easier. It makes expectations clearer, particularly around trial blinding, patient monitoring, abuse potential, repeat dosing and the role of psychotherapy. A new Microdose feature explores what these standards mean for the industry, why scalability is becoming a defining issue and how non-hallucinogenic neuroplastogens such as Enveric’s EB-003 may offer a differentiated development path. Read the full article: microdose.buzz/news/fdas-new… #FDA #Neuroplastogens #Neuroplasticity #PsychedelicMedicine #MentalHealthInnovation #DrugDevelopment #Biotech #ENVB